

Matthew Bio, Ph.D., joins Snapdragon Chemistry as Chief Scientific Officer

BOSTON, MA, USA, September 10, 2015 /EINPresswire.com/ -- [Snapdragon Chemistry, Inc.](http://SnapdragonChemistry, Inc.), a company that combines sophisticated solutions and services with preeminent scientific expertise to help companies harness the advantages and opportunities of continuous flow synthesis, today announced that [Matthew \(Matt\) Bio](#), Ph.D., is joining as its Chief Scientific Officer and a member of the leadership team.

Matt Bio comes to Snapdragon Chemistry from Amgen Inc., where he most recently served as Director of Process Development and Head of the Synthetic and Hybrid Technologies group. At Amgen, Dr. Bio was responsible for setting the scientific direction of process development for synthetic drug candidates and for leading development of the first continuous process at Amgen. Matt also drove innovation in the area of biologic-synthetic hybrids, developing new technologies for the manufacture of hybrid modality drug candidates.

"Matt brings a wealth of leadership and expertise in cutting-edge chemical technologies and innovation to Snapdragon Chemistry during an exciting point in our company's growth," said Tim Jamison, CEO of Snapdragon and Head of MIT's Chemistry Department. "Matt shares our passion for helping companies harness continuous flow synthesis to drive unparalleled value in their operations. He has a truly

outstanding track record of delivering innovation in process research and brings a significant amount of leadership and insight on industrial operations that will allow us to serve our clients in a more significant way."



Matthew Bio - Snapdragon Chemistry's Chief Scientific Officer

his creativity and ingenuity, Aaron Beeler has been instrumental in building Snapdragon Chemistry into a leading provider of continuous flow solutions,” said Tim Jamison, CEO, “and his ability now to focus on driving innovation into our client solutions will only further serve to strengthen our value proposition.”

“Snapdragon Chemistry is uniquely positioned - with deep expertise in developing meaningful process solutions in flow chemistry - to accelerate the adoption of continuous manufacturing across a number of industries,” said Dr. Bio. “I am excited to be part of the team that is expanding upon the expertise and innovations developed from Tim Jamison’s and Aaron Beeler’s leading research in the field, in order to deliver value to a variety of industries.”

Dr. Bio holds a Ph.D. in Organic Chemistry from Columbia University, where he was a Bristol-Myers Squibb and American Chemical Society Graduate Fellow, and a B.A. in Natural Science from Muhlenberg College. Prior to Amgen, Dr. Bio held roles of increasing responsibility in Merck & Co., Inc.’s process research department.

About Snapdragon Chemistry, Inc.

Snapdragon Chemistry is headquartered in Boston, MA and is a leading provider of flow chemistry solutions and services. It offers a wide-range of solutions, including reaction development and optimization (such as multi-step synthesis in flow), proactive portfolio analysis to identify specific opportunities to apply flow chemistry to process development and discovery challenges. Snapdragon Chemistry differentiates itself based on a strong portfolio of intellectual property, a network of world-class scientists that are shaping the field of continuous flow chemistry, and an unrelenting focus on customer service.

For more information, please visit www.snapdragonchemistry.com.

Tim Jamison, CEO
Snapdragon Chemistry, Inc.
617-902-0209
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.

